Efficacy and toxicity evaluation
Response was defined as the best observed response after at least one
cycle of Doxorubicin Hydrochloride Liposome plus irinotecan regimen.
According to the RECIST (Response Evaluation Criteria of Solid Tumors)
standard for efficacy evaluation, it is divided into: complete response
(CR), partial response (PR), stable (SD) and progression (PD).
Progression Free Survival (PFS) is defined as the time from the start of
the Doxorubicin Hydrochloride Liposome plus irinotecan regimen to the
progression of the disease or the time of the last follow-up. Overall
Survival (OS) is defined as the time from the start of the Doxorubicin
Hydrochloride Liposome plus irinotecan regimen to death or the last
follow-up.
Toxicity assessment is based on the Common Terminology Criteria for
Adverse Events (CTCAE 4.03).